Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS

TURKU, Finland and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will hold a conference call today to discuss new positive clinical data from the Company's ongoing Phase I/II BEXMAB study. Conference Call and Webcast Wednesday, July 19, 2023, at 8:30 am ET. The live call may be accessed by dialing (877) 407-3982 for callers in the US and (201)

Related Keywords

Boston ,Massachusetts ,United States ,Finland ,Jukka ,Lapland ,Christopher Golden ,Juha Karttunen ,Sandy Jamieson ,Jenniferc Smith Parker ,Jo Turner ,Faron Pharmaceuticals Ltd ,Faron Pharmaceuticals ,Head Of Communications ,Peel Hunt ,Cairn Financial Advisers ,First North ,Investor Relations Calendar ,Certified Adviser ,Nasdaq First ,Biopharmaceutical Company ,The Company ,Company ,Immune System ,Mmunotherapies ,